NEW YORK (360Dx) – VolitionRx today priced a public offering of 3.5 million shares of its common stock at $2.40 per share.
Gross proceeds from the offering, expected to close on or about March 13, are expected to be about $8.4 million. The company has also granted the offering's underwriters a 30-day option to cover any overallotments. Oppenheimer is the sole book-running manager for the offering. National Securities is the co-manager.
VolitionRx plans to use net proceeds for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes, it said. In September, the Belgium-based company was awarded a loan and non-repayable grant totaling $1.5 million.
VolitionRx develops blood tests for diagnosing cancers. Its Nucleosomics platform identifies and measures nucleosomes to identify the presence of disease